lactic acid cream
stratus pharamceuticals, inc - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - lactic acid 11.34 g in 113.4 g
lactic acid lotion
stratus pharamceuticals, inc - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - lactic acid 35.484 ml in 354.84 ml
hydroxyurea capsule
teva pharmaceuticals usa, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)] . there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see data) . advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea c
hydroxyurea capsule
avkare - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology ( 12.1)] . there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see data). advise women of the potential risk to
urea hydrating topical- urea aerosol, foam
acella pharmaceuticals - urea (unii: 8w8t17847w) (urea - unii:8w8t17847w) - urea 35 g in 100 g - indications and usage for enzymatic debridement and promotion of normal healing of surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris, or eschar. topically applied urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, and dry, rough skin, as well as corns and calluses and damaged, ingrown and devitalized nails. contraindications known hypersensitivity to any of the listed ingredients.
hydroxyurea- hydroxyurea capsule
teva pharmaceuticals usa, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)] . there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see data). advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea c
hydroxyurea capsule
par pharmaceutical, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules, usp is indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1) ]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see data ). advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with
hydroxyurea capsule
american health packaging - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see data). advise women of the potential risk to a fetus and to avoid becoming pregnant while be
hydroxyurea capsule
cardinal health 107, llc - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules, usp is indicated for the treatment of: hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see data). advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea capsules. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically
hydroxyurea capsule
golden state medical supply, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules, usp is indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1) ]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis ( see data ). advise women of the potential risk to a fetus and to avo